- Ilika
- 18 August 2025 12:55:08
Source: Sharecast
The AIM-traded firm said the milestone, which came after commissioning equipment earlier in the year, marked the final technical validation step before full-scale production.
It said the line incorporated advanced deposition, alignment and patterning systems required for medical-grade micro-battery manufacturing.
Production had now started to support product testing and initial customer deliveries.
The achievement triggered a 10-year manufacturing agreement signed in 2023 under which Cirtec would produce Ilika’s Stereax battery portfolio.
“This manufacturing milestone demonstrates the successful technology transfer of our proprietary Stereax platform to commercial production scale,” said chief executive Graeme Purdy.
“The strong customer interest we're seeing validates the market need for miniaturised solid-state batteries in medical devices.
“With the combination of Ilika's expertise and Cirtec Medical's world-class manufacturing capabilities, we are well-positioned to meet growing customer demand in 2025 and beyond.”Ilika said the collaboration aimed to meet rising demand for miniaturised power solutions in implantable medical devices by combining its solid-state battery technology with Cirtec’s established expertise in medical device production.
Initial deliveries of the Stereax M300 were targeted to start later in 2025.
“The successful qualification of Stereax battery production strengthens our position as a leading manufacturer of next-generation medical devices,” commented Ed Philbin, interim chief executive of Cirtec Medical.
“By incorporating Ilika's innovative micro-battery technology into our vertically integrated manufacturing capabilities, we can offer our customers unprecedented opportunities for device miniaturisation and enhanced performance in implantable medical applications.”
At 1222 BST, shares in Ilika were up 5.02% at 44.95p.
Reporting by Josh White for Sharecast.com.